Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration

Arquivos Brasileiros de Oftalmologia

Volumn 70, Issue 5, 2007, Pages 771-776

  Isaac, David Leonardo Cruvinel ^a,b   de Ávila, Marcos Pereira ^a   Cialdini, Arnaldo Pacheco ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b UFG ^*  (Brazil)

Author keywords

Choroidal neovascularization; Comparative study; Macular degneration; Patient selection; Perimetry methods; Vision tests

Indexed keywords

EID: 39049156985     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492007000500009     Document Type: Article

References (22)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-43.
2. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-relatad macular degeneration in the United States. Eye Diseases Prevalence Research Group. Arch Ophthalmol. 2004;122(4):564-72.
3. Loewenstein A, Bressler NM. Neovascular (exudative) age-related macular degeneration. In. Guyer D, editor. Retina-vitreous-macula. Philadelphia, PA: W.B.Saunders; 1999. p.94-121.
4. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109(9):1242-57.
5. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25(2):119-34. Review.
6. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsoid M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. New Engl J Med. 2004;351(27):2805-16.
7. Heier JS, Antoszyk NA, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006; 113(4):633-642.
8. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26(4):383-90.
9. Rosenfeld J, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331-5.
10. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G. Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136(3): 407-18.
11. Augustin AJ, Offermann JL, Lutz J, Schmidt-Erfurth U, Tornambe P. Comparsion of the original Amsler grid with the modified Amsler grid. results for patients with age-related macular degeneration. Retina. 2005;25(4):443-5.
12. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol. 1986;104(4):513-4.
13. Schuchard RA. Validity and interpretation of Amsler grid reports. Arch Ophthalmol. 1993;111(6):776-80.
14. Achard OA, Safran AB, Duret FC, Ragama E. Role of the completion phenomenon in the evaluation of Amsler grid results. Am J Ophthalmol. 1995;120(3):322-9.
15. Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H, Springer A, Schachat AP, Bressler NM, Bressler SB, Cooney MJ, Alster Y, Rafaeli O, Malach R; Preferential Hyperacuity Perimeter Research Group. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina. 2005;25(3):296-303.
16. Loewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruk E, et al. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology. 2003;110(5):966-70.
17. Alster Y, Bressler NM, Bressler SB, Brimacombe JA, Crompton RM, Duh YJ, Gabel VP, Heier JS, Ip MS, Loewenstein A, Packo KH, Stur M, Toaff T; Preferential Hyperacuity Perimetry Research Group. Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology. 2005;112(10):1758-65.
18. Lewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruch E, et al. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology. 2003;110(5):966-70. Comment in: Ophthalmology. 2005;112(2):357; author reply 357.
19. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119(10):1417-36.
20. Zaidi FH, Cheong-Leen R, Gair EJ, Weir R, Sharkawi E, Lee N, et al. The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. The West London Survey. Eye. 2004;18(5):503-8.
21. Werner EB, Adelson A, Krupin T. Effect of patient experience on the results of automated perimetry in clinically stable glaucoma patients. Ophthalmology. 1988;95(6):764-7.
22. Heijl A, Lindgren G, Olsson J. The effect of perimetric experience in normal subjects. Arch Ophthalmol. 1989;107(1):81-6.